Regulatory Highlights

Andrew Teasdale

doi:10.1021/acs.oprd.0c00288

2020-07-08

PRE

Andrew Teasdale

Matthew E. Popkin

Stuart Finnie

DOI：10.1021/acs.oprd.0c00288

原文链接

原文求助

摘要

AI总结

对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

Organic Process Research and Development

IF:

3.5

论文数:

5.8K

被引数:

1.1W

机构

暂无机构信息

引用论文

Examining Manufacturing Readiness for Breakthrough Drug Development

AAPS PHARMSCITECH

IF4

2015-11-25

OAAI

Dye, Earl; Sturgess, Annie; Maheshwari, Gargi; May, Kimberly; Ruegger, Colleen; Ramesh, Usha; Tan, Heow; Cockerill, Keith; Groskoph, John; Lacana, Emanuela; Lee, Sau; Miksinski, Sarah Pope

Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2017-03-01

PREAI

Harvey, James; Fleetwood, Andrew; Ogilvie, Ron; Teasdale, Andrew; Wilcox, Phil; Spanhaak, Steven